Understanding why CAR T cells don't last in leukemia treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on pediatric and young adult patients with acute lymphoblastic leukemia (ALL) who are set to receive CD19-targeted CAR T-cell therapy. It aims to investigate the persistence of CAR T cells over time and identify the factors that may influence their longevity. By monitoring these patients, researchers hope to gather valuable data that can inform future treatments and improve outcomes for ALL patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Children and young adults (age 25 years or younger) with relapsed/refractory ALL who are planned to receive licensed CD19-targeted CAR-T cell treatment (Tisagenlecleucel)
2. Written informed consent

Exclusion Criteria:

1. Patients receiving an alternate CD19-directed CAR T-cell product on a clinical trial
2. Any reason that in the opinion of the investigator, patients won't be able to adhere to the protocol

Where it's running

• Great Ormond Street Hospital
  London, United Kingdom Recruiting
• University College London Hospital
  London, United Kingdom Recruiting
• Royal Manchester Children's Hospital
  Manchester, United Kingdom Recruiting

Study contacts

• Study coordinator: CARPERS Trial Manager
• Email: ctc.carpers@ucl.ac.uk
• Phone: 442031084189

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CAR-T cell therapy for adults with relapsed or refractory leukemia and lymphoma

  This study is testing a new CAR-T cell therapy to see if it can help adults with tough-to-treat leukemia or lymphoma feel better and fight their cancer.

  Recruiting at 2 sites Phase 1 Fudan University · Nanchang, Jiangxi and 1 other locations · NCT06445803

• Treatment for relapsed or refractory CD19+ lymphoid diseases using engineered T cells

  This study is testing a new treatment using specially modified immune cells to help adults and children with certain types of blood cancers that haven't responded to other therapies.

  Recruiting at 2 sites Phase 1/2 University Hospital Heidelberg · Heidelberg and 1 other locations · NCT03676504

• In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

  This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07775508

• Point-of-care MB-CART19.1 CAR-T therapy for relapsed or refractory B‑ALL

  This will test whether autologous, point-of-care manufactured CD19-directed CAR-T cells (MB-CART19.1) can treat children and adults with relapsed or refractory B‑cell acute lymphoblastic leukemia.

  Recruiting King Hussein Cancer Center · Amman · NCT07371403

• Nanobody CD5 CAR‑T for relapsed or refractory CD5‑positive T‑cell cancers

  This will test a CD5-targeted CAR‑T cell treatment using patients' own or donor-derived cells to try to help people with relapsed or refractory CD5+ T‑cell leukemias and lymphomas.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07070323

• CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

  This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.

  Recruiting at 3 sites Phase 1/2 Beijing GoBroad Hospital · Beijing and 2 other locations · NCT07022964

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.